« Back
Home /
Mouse LY75 / CD205 Protein, His Tag (MALS verified)

Mouse LY75 / CD205 Protein, His Tag (MALS verified)

Item no.	LY5-M52H5-1mg
Manufacturer	ACROBiosystems
Amount	250 ug x 4
Quantity options	100 ug 250 ug x 4
Category	Peptides & Proteins Recombinant Proteins
Type	Proteins Recombinant
Format	Solid
Specific against	Mouse (Murine, Mus musculus)
Host	HEK293
Conjugate/Tag	Unconjugated, HIS
Purity	90%
Citations	(1) Eugenio Gaudio, et al. Haematologica. 2020. 105(11):2584-2591. (2) Sadia Mehdi, et al. Int J Mol Sci. 2020. 21(14):4992. (3) Sheikh Tasnim Jahan, et al. Int J Nanomedicine. 2015. 10:7371-84.
NCBI	NP_038853.2
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	LY75,CD205,DEC-205,CLEC13B,Lymphocyte antigen 75,gp200-MR6
Shipping Condition	Room temperature
Available
Manufacturer - Category	Protein
Manufacturer - Conjugate / Tag	C-10xHis, Unconjugated
Shipping Temperature	RT
Storage Conditions	-20°C
Molecular Weight	190.0 kDa
Manufacturer - Species	Mouse
Manufacturer - Format	Powder
Description	lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.
Background	lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.
Molecule	LY75
Exp Region	Ser 28 - Asp 1667
Characteristics	This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 190.0 kDa. The protein migrates as 230-260 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin	1.0 EU per μg
Buffer	PBS, pH7.4
Stability	● -20°C to -70°C for 12 months in lyophilized state; ● -70°C for 3 months under sterile conditions after reconstitution._x000D_For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Protectant	trehalose

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

LY5-M52H5-1mg-datasheet.pdf

LY5-M52H5-1mg-safety-datasheet.pdf